A Study to Evaluate the Safety and Immunogenicity of the V3-region Directed Immunogens DV700P-RNA Followed by DV701B1.1-RNA in Adults Without HIV

Inclusion Criteria: * Understands the study and agrees to complete the consent process. * Can attend all clinic visits until the end of the study. * Agrees to follow all study procedures. * Will not join another study with experimental treatments during this trial, unless approved by both study sponsors. * Generally healthy according to the study doctor. * Physical exam and lab results show no major issues that could affect safety or study results. * Agrees to discuss HIV risk and prevention. * Hemoglobin levels: at least 11.0 g/dL for women and 13.0 g/dL for men. * White blood cell count between 2,500 to 12,000/mm³ (higher levels okay if health is otherwise good and approved). * Platelet count between 125,000 to 550,000/mm³. * ALT enzyme level less than 2.5 times the upper limit of normal. * Serum creatinine level within 1.1 times the upper limit of normal. * Serum calcium level at least 8.5 mg/dL. * Blood pressure within acceptable range (systolic 90-140 mmHg, diastolic 50-90 mmHg), with average below 140/90 mmHg and no single reading over 160/100 mmHg. * Negative HIV test. * Negative for Hepatitis C. * Negative for Hepatitis B. * Women who can become pregnant must use effective contraception from 21 days before joining the study until 8 weeks after the last vaccination and must have a negative pregnancy test on enrollment day. * Women of pregnancy potential must agree not to seek pregnancy through methods like IVF from 21 days before joining the study until 8 weeks after the last vaccination. Exclusion Criteria: * Breastfeeding or pregnant. * Body mass index (BMI) of 40 or higher, unless in good health and approved. * Diabetes, unless it is well-controlled Type 2 diabetes or gestational diabetes. * Previous or current investigational HIV vaccine recipients (placebo recipients are allowed). * Received non-HIV investigational vaccines within the last year, unless they are now licensed or authorized. * Immunodeficiency or medications that impair immune response, such as high-dose steroids. * Received blood products or immunoglobulin within 16 weeks before enrollment. * Received certain vaccines within the last 4 weeks before enrollment. * Received other vaccines within 14 days before enrollment. * History of myocarditis or pericarditis. * Started allergy immunotherapy in the past year (unless stable and approved). * Taken investigational research agents recently. * Serious allergic reactions to any mRNA vaccine or drugs containing polyethylene glycol. * History of hereditary or acquired angioedema. * Any episode of hives (urticaria) within the past year. * Chronic hives (urticaria). * Hives previously caused by immunization. * Bleeding disorder that would make study procedures unsafe. * Seizures or use of seizure medications in the past 3 years. * Absence of spleen or non-functional spleen. * Active duty and reserve US military personnel. * Any other significant condition that could affect safety or participation, including substance use, psychiatric disorders, recent suicide attempts, or cancer with potential for recurrence. * Asthma that requires frequent or high-dose medication, recent emergency care, or multiple daily medications. * History of certain immune-mediated conditions (mild, localized conditions may be okay). * Allergy to local anesthetics like Novocaine or Lidocaine. * Difficulty with venous access, such as history of intravenous drug use or problems with blood draws.